Idecabtagene Vicleucel Infusion Suppliers & Bulk Manufacturers
Available Forms: IV Infusion
Available Strengths: Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells
Reference Brands: Abecma(US & EU)
Category: Cell & Gene Therapies
Idecabtagene Vicleucel Infusion is available in IV Infusion and strengths such as Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Idecabtagene Vicleucel Infusion is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Idecabtagene Vicleucel Infusion can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description:
Idecabtagene vicleucel (Abecma) is regulated in the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in line with GMP and MDR standards. FDA approval involved extensive clinical validation, safety assessment, and comparability data. In the EU, CE marking certifies conformity with MDR regulations. The product undergoes validation, stability testing, and audits, with comprehensive documentation including clinical trial results, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to innovative, life-saving CAR T-cell therapies for multiple myeloma and other hematologic malignancies globally, supporting improved patient outcomes and advanced cancer care.
Frequently Asked Questions
Related Products
Darleukin Injection
Strength: A standardized dose of 120 million adipose-derived stem cells per injection
Form: Intralesional injection
Reference Brands: Alofisel(US & EU)
View Details
Etranacogene Dezaparvovec. Infusion
Strength: Single infusion product designed to produce sustained factor IX levels in hemophilia B patients, dosage individualized based on patient weight
Form: Intravenous infusion
Reference Brands: Hemgenix (US & EU)
View Details
Elivaldogene Autotemcel Infusion
Strength: A personalized gene therapy designed to halt or slow ALD progression, dosed based on weight, administered as a single infusion in specialized treatment centers
Form: Intravenous infusion
Reference Brands: Skysona(US & EU)
View Details
Valoctocogene Roxaparvovec Infusion
Strength: A single-dose gene therapy designed to increase factor VIII production in hemophilia A patients
Form: Intravenous infusion
Reference Brands: Roctavian(US & EU)
View DetailsQuick Response Guaranteed | Verified Suppliers